心衰1号中药联合沙库巴曲缬沙坦治疗慢性心力衰竭伴低血压临床观察  

Clinical Observation of Xinshuai No.1 Formula(心衰1号)Combined with Sacubitril Valsartan in Treatment of Chronic Heart Failure with Hypotension

作　　者：董晓楠 王俊 毛建芳 刘金波 DONG Xiaonan;WANG Jun;MAO Jianfang;LIU Jinbo(Qingdao Integrated Traditional Chinese and Western Medicine Hospital,Qingdao 266002,Shandong,China)

机构地区：[1]山东青岛中西医结合医院,山东青岛266002

出　　处：《中华中医药学刊》2025年第2期164-167,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家中医药管理局中医药科学技术研究专项(2018ZX691)。

摘　　要：目的研究心衰1号中药联合沙库巴曲缬沙坦治疗慢性心力衰竭伴低血压的临床效果。方法选取2022年8月—2023年7月医院收治的慢性心力衰竭伴低血压患者100例,按照随机数表法分为观察组和对照组,每组50例。对照组采用沙库巴曲缬沙坦治疗,观察组采用心衰1号中药联合沙库巴曲缬沙坦治疗,疗程4周。观察并比较两组患者的心功能疗效、血压变化、血清炎症因子、生活质量及不良反应情况。结果观察组心功能疗效显效率68.00%(34/50),显著高于对照组的48.00%(24/50)(P<0.05)。治疗后两组患者收缩压、舒张压均显著升高(P<0.05),且观察组显著高于对照组(P<0.05)。治疗前两组血清超敏C反应蛋白(Hypersensitive C-reactive protein,hs-CRP)、白细胞介素6(Interleukin-6,IL-6)、肿瘤坏死因子α(Tumour necrosis factor-α,TNF-α)比较差异均无统计学意义(P>0.05),治疗后两组以上各血清炎症因子指标均显著降低,且观察组显著低于对照组(P<0.05)。治疗后两组患者中文版本明尼苏达心功能不全生命质量量表(Minnesota living with heart failure questionnaire,MLHFQ)躯体领域评分及总分均显著降低,观察组MLHFQ躯体领域评分及总分显著高于对照组(P<0.05)。观察组、对照组不良反应发生率分别8.00%(4/50)、10.00%(5/50),差异无统计学意义(P>0.05)。结论心衰1号中药联合沙库巴曲缬沙坦治疗慢性心力衰竭伴低血压的临床效果满意,能够更好地改善心功能状况及血压水平,降低机体炎症反应,提高患者生活质量,并且治疗安全性可靠。Objective To study the clinical effect of Xinshuai No.1 Formula(心衰1号)combined with sacubitril valsartan in the treatment of chronic heart failure with hypotension.Methods A hundred patients with chronic heart failure and hypotension treated in the hospital from August 2022 to July 2023 were selected and divided into observation group and control group according to the random number table method,with 50 patients in each group.The patients in the control group were treated with sacubitril valsartan,and those in the observation group were treated with Xinshuai No.1 Formula combined with sacubitril valsartan for 4 weeks.The efficacy of cardiac function,blood pressure changes,serum inflammatory factors,quality of life and adverse reactions were observed and compared between the two groups.Results The effective rate of cardiac function in the observation group was 68.00%(34/50),which was significantly higher than that in the control group(48.00%,24/50)(P<0.05).After treatment,the systolic blood pressure and diastolic blood pressure of the two groups were significantly increased(P<0.05),and the pressures of the observation group were significantly higher than those of the control group(P<0.05).There was no significant difference in serum high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)or tumor necrosis factor-α(TNF-α)between the two groups before treatment(P>0.05).After treatment,the serum inflammatory factors of the two groups were significantly reduced,and the levels of the observation group were significantly lower than those of the control group(P<0.05).After treatment,the physical domain score and total score of the Chinese version of the Minnesota Heart Failure Quality of Life Scale(MLHFQ)in the two groups were significantly decreased,and the physical domain score and total score of the MLHFQ in the observation group were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group was 8.00%(4/50)and 10.00%(5/5

关 键 词：慢性心力衰竭 低血压 心衰1号中药 沙库巴曲缬沙坦 心功能 炎症因子 生活质量 

分 类 号：R259.416[医药卫生—中西医结合]